Science Explorer Back to mapMap

Most cited papers from Neurim Pharmaceuticals (Israel)

What are the most cited papers from Neurim Pharmaceuticals (Israel)?

The most cited paper from Neurim Pharmaceuticals (Israel) is "New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation" (Nava Zisapel, 2018), with 868 citations. Next come "Improvement of sleep quality in elderly people by controlled-release melatonin" (478) and "Melatonin Replacement Therapy of Elderly Insomniacs" (348).

Showing 50 of 60 papers. Every paper with more than 25 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation Nava Zisapel · British Journal of Pharmacology Open access 10 Jan 2018 868
2 Improvement of sleep quality in elderly people by controlled-release melatonin Doron Garfinkel, Moshe Laudon, Dina Nof et al. · The Lancet Aug 1995 478
3 Melatonin Replacement Therapy of Elderly Insomniacs Iris Haimov, Peretz Lavie, Moshe Laudon et al. · SLEEP Sep 1995 348
4 Sleep disorders and melatonin rhythms in elderly people Iris Haimov, Moshe Laudon, Nava Zisapel et al. · BMJ Open access 16 Jul 1994 316
5 Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children With Autism Spectrum Disorder Paul Gringras, Tali Nir, John Breddy et al. · Journal of the American Academy of Child & Adolescent Psychiatry Open access 19 Sep 2017 312
6 Improving Postoperative Immune Status and Resistance to Cancer Metastasis Yael Goldfarb, Liat Sorski, Marganit Benish et al. · Annals of Surgery 26 Feb 2011 267
7 Prolonged‐release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects Patrick Lemoine, Tali Nir, Moshe Laudon et al. · Journal of Sleep Research 21 Nov 2007 263
8 Efficacy of prolonged release melatonin in insomnia patients aged 55–80 years: quality of sleep and next-day alertness outcomes Alan G. Wade, Ian Ford, Gordon M. Crawford et al. · Current Medical Research and Opinion 14 Sep 2007 237
9 Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety Alan G. Wade, Ian Ford, Gordon M. Crawford et al. · BMC Medicine Open access 16 Aug 2010 180
10 Long-Term Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children with Autism Spectrum Disorder Athanasios Maras, Carmen M Schroder, Beth Ann Malow et al. · Journal of Child and Adolescent Psychopharmacology Open access 22 Aug 2018 179
11 Sleep, Growth, and Puberty After 2 Years of Prolonged-Release Melatonin in Children With Autism Spectrum Disorder Beth Ann Malow, Robert L. Findling, Carmen M Schroder et al. · Journal of the American Academy of Child & Adolescent Psychiatry Open access 23 Jan 2020 176
12 Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer’s disease: a 6-month, randomized, placebo-controlled, multicenter trial Moshe Laudon, Alan G. Wade, Mildred V. Farmer et al. · Clinical Interventions in Aging Open access Jun 2014 174
13 Melatonin Reduces Night Blood Pressure in Patients with Nocturnal Hypertension Ehud Grossman, Moshe Laudon, Rıdvan Yalçin et al. · The American Journal of Medicine 24 Sep 2006 168
14 Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy Damien Léger, Moshe Laudon, Nava Zisapel · The American Journal of Medicine 2004 159
15 Clinical trials of controlled‐release melatonin in children with sleep–wake cycle disorders James E. Jan, Don Hamilton, Nadine Seward et al. · Journal of Pineal Research May 2000 153
16 Therapeutic Effects of Melatonin Receptor Agonists on Sleep and Comorbid Disorders Moshe Laudon, Anat Frydman‐Marom · International Journal of Molecular Sciences Open access 9 Sep 2014 149
17 Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials Moshe Laudon, Grossman, Nava Zisapel · Vascular Health and Risk Management ReviewOpen access Sep 2011 149
18 Pediatric Prolonged-Release Melatonin for Sleep in Children with Autism Spectrum Disorder: Impact on Child Behavior and Caregiver’s Quality of Life Carmen M Schroder, Beth Ann Malow, Athanasios Maras et al. · Journal of Autism and Developmental Disorders Open access 11 May 2019 139
19 The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia R. Luthringer, Muriel Muzet, Nava Zisapel et al. · International Clinical Psychopharmacology 10 Aug 2009 138
20 Effects of prolonged‐release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers Sarah Otmani, A. Demazières, Corinne Staner et al. · Human Psychopharmacology Clinical and Experimental 2 Sep 2008 131
21 Efficacy and safety of prolonged-release melatonin in insomnia patients with diabetes: a randomized, double-blind, crossover study Nava Zisapel, Garfinkel, V Zorin et al. · Diabetes Metabolic Syndrome and Obesity Open access Aug 2011 129
22 Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term response Alan G. Wade, Gordon M. Crawford, Ian Ford et al. · Current Medical Research and Opinion 24 Nov 2010 129
23 Determination of the minimal clinically significant difference on a patient visual analog sleep quality scale Nava Zisapel, Tali Nir · Journal of Sleep Research 24 Nov 2003 123
24 NEU-P11, a novel melatonin agonist, inhibits weight gain and improves insulin sensitivity in high-fat/high-sucrose-fed rats Meihua She, Xiaojian Deng, Zhenyu Guo et al. · Pharmacological Research 27 Jan 2009 117
25 A novel melatonin agonist Neu-P11 facilitates memory performance and improves cognitive impairment in a rat model of Alzheimer' disease Pingping He, Xin-Ping Ouyang, Shouhong Zhou et al. · Hormones and Behavior 4 May 2013 96
26 Melatonin: From Pharmacokinetics to Clinical Use in Autism Spectrum Disorder Sébastien Lalanne, Claire Fougerou‐Leurent, George M. Anderson et al. · International Journal of Molecular Sciences Open access 2 Feb 2021 91
27 In vivo suppression of NK cell cytotoxicity by stress and surgery: Glucocorticoids have a minor role compared to catecholamines and prostaglandins Ella Rosenne, Liat Sorski, Lee Shaashua et al. · Brain Behavior and Immunity Open access 12 Dec 2013 88
28 Cross‐cultural validation of the Leeds sleep evaluation questionnaire (LSEQ) in insomnia patients Ricardo Tarrasch, Moshe Laudon, Nava Zisapel · Human Psychopharmacology Clinical and Experimental Dec 2003 87
29 Serum levels of sex hormones and corticosterone throughout 4- and 5-day estrous cycles in Fischer 344 rats and their simulation in ovariectomized females Sara Haim, Guy Shakhar, Ella Rossene et al. · Journal of Endocrinological Investigation Oct 2003 81
30 Massage Therapy by Mothers Enhances the Adjustment of Circadian Rhythms to the Nocturnal Period in Full-Term Infants Sari Goldstein Ferber, Moshe Laudon, Jacob Kuint et al. · Journal of Developmental & Behavioral Pediatrics Dec 2002 75
31 Drugs for insomnia Nava Zisapel · Expert Opinion on Emerging Drugs 11 Jun 2012 70
32 Effect of controlled-release melatonin on sleep quality, mood, and quality of life in subjects with seasonal or weather-associated changes in mood and behaviour Sami Leppämäki, Timo Partonen, Olli Vakkuri et al. · European Neuropsychopharmacology May 2003 70
33 Prolonged-Release Melatonin for Children With Neurodevelopmental Disorders Hélène De Leersnyder, Nava Zisapel, Moshe Laudon · Pediatric Neurology Jul 2011 69
34 Cardiovascular effects of melatonin receptor agonists Ludovít Paulis, Fedor Šimko, Moshe Laudon · Expert Opinion on Investigational Drugs 23 Aug 2012 66
35 Improvement of sleep quality by controlled-release melatonin in benzodiazepine-treated elderly insomniacs Doron Garfinkel, Moshe Laudon, Nava Zisapel · Archives of Gerontology and Geriatrics Mar 1997 64
36 Subjective assessment of the effects of CNS‐active drugs on sleep by the Leeds sleep evaluation questionnaire: a review Nava Zisapel, Moshe Laudon · Human Psychopharmacology Clinical and Experimental 2003 63
37 Antidepressant- and anxiolytic effects of the novel melatonin agonist Neu-P11 in rodent models Shaowen Tian, Moshe Laudon, Li Han et al. · Acta Pharmacologica Sinica Open access 28 Jun 2010 62
38 Melatonin Production in Healthy Infants: Evidence for Seasonal Variations Yakov Sivan, Moshe Laudon, Rivi Tauman et al. · Pediatric Research 2001 61
39 CD44 Splice Variants as Potential Players in Alzheimer’s Disease Pathology Elhanan Pinner, Yaron Gruper, Micha Ben Zimra et al. · Journal of Alzheimer s Disease 25 May 2017 56
40 Prolonged-release melatonin for insomnia – an open-label long-term study of efficacy, safety, and withdrawal Nava Zisapel, Lemoine, Doron Garfinkel et al. · Therapeutics and Clinical Risk Management Open access Jul 2011 54
41 Preliminary Observations on APOE ϵ4 Allele and Progression of Disability in Multiple Sclerosis Joab Chapman, Constanatin Sylantiev, Puiu Nisipeanu et al. · Archives of Neurology Dec 1999 54
42 Melatonin production in infants Riva Tauman, Nava Zisapel, Moshe Laudon et al. · Pediatric Neurology May 2002 46
43 Melatonin receptors in diabetes: A potential new therapeutical target? Meihua She, Moshe Laudon, Weidong Yin · European Journal of Pharmacology 24 Aug 2014 45
44 Effects of prolonged‐release melatonin and zolpidem on postural stability in older adults Sarah Otmani, DEBORAH A. METZGER, Nathalie Guichard et al. · Human Psychopharmacology Clinical and Experimental 20 Feb 2012 45
45 High NK cell activity in recurrent miscarriage: what are we really measuring? Keren Shakhar · Human Reproduction 9 May 2006 43
46 Efficacy and safety of prolonged-release melatonin for insomnia in middle-aged and elderly patients with hypertension: a combined analysis of controlled clinical trials Amnon Katz, Lemoine, Wade et al. · Integrated Blood Pressure Control Open access 2012 40
47 Neuroprotective mechanism of the novel melatonin derivative Neu-P11 in brain ischemia related models Izaskun Buendía, Vanessa Gómez‐Rangel, Laura González‐Lafuente et al. · Neuropharmacology 16 Jul 2015 40
48 The relationship between melatonin and cortisol rhythms: clinical implications of melatonin therapy Nava Zisapel, Ricardo Tarrasch, Moshe Laudon · Drug Development Research Jul 2005 39
49 Lasting treatment effects in a postmarketing surveillance study of prolonged-release melatonin Göran Hajak, Kathrin Lemme, Nava Zisapel · International Clinical Psychopharmacology Open access 23 Jul 2014 39
50 Putative melatonin receptors in benign human prostate tissue. Moshe Laudon, Eli Gilad, Haim Matzkin et al. · The Journal of Clinical Endocrinology & Metabolism Open access Apr 1996 39

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.